EM1507D "Immunotherapy: A New Era in Cancer Treatment" (IM GR-071015)
Drugs that manipulate the immune system have recently been shown to have durable clinical responses in patients with melanoma. In this protocol and presentation, we discuss the scientific and clinical milestones that led to that achievement. Each of these milestones was surrounded by controversy and there are lessons to be learned in how the challenges were overcome.
UT Southwestern faculty, fellows, residents and medical students, community physicians, nurse clinicians, physician assistants and nurses.
At the conclusion of this activity, the participant should be able to:
- Learn the experimental rationale for cancer immunosurveillance
- Learn how CTLA-4 was discovered and the rationale for targeting CTLA-4 in cancer
- Review clinical trials for immunotherapeutic agents
Deepak Nijhawan, M.D., Ph.D.
Division of Hematology and Oncology
Department of Biochemistry
- 1.00 AMA
- 1.00 Attendance